Cancer urothéliaux métastatiques : le futur et les perspectives

25 novembre 2008

Auteurs : T. Lebret, A. Méjean
Référence : Prog Urol, 2008, 18, S277, suppl. S7
   
 
 

 

 
Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser

   

 

 
 
 

Références

 

Tannock I., Gospodarowicz M., Connolly J., Jewett M. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience J Urol 1989 ;  142 : 289-292 [cross-ref]
 
Munoz A., Barcelo J.R., Lopez-Vivanco G. Chemotherapy for bladder cancer N Engl J Med 2003 ;  349 : 2272-2273 [cross-ref]
 
Von Der Maase H., Sengelov L., Roberts J.T., et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J Clin Oncol 2005 ;  23 : 4602-4608 [cross-ref]
 
Sternberg C.N., de Mulder P.H., Schornagel J.H., et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no 30924 J Clin Oncol 2001 ;  19 : 2638-2646 [cross-ref]
 
Papatsoris A.G., Kachrilas S., Gekas A. Where are we with the treatment of metastatic bladder cancer? Expert Opin Investig Drugs 2007 ;  16 : 1311-1314 [cross-ref]
 
Sternberg C.N., Donat S.M., Bellmunt J., Millikan R.E., Stadler W., De Mulder P., Sherif A., von der Maase H., Tsukamoto T., Soloway M.S. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer Urology 2007 ;  69 : 62-79 [inter-ref]
 
Siefker-Radtke A. Systemic chemotherapy options for metastatic bladder cancer Expert Rev Anticancer Ther 2006 ;  6 : 877-885 [cross-ref]
 
Cussenot O., Fournier G. Génétique et urology. Rapport du congrès 2000 de l’AFU Prog Urol 2000 ;  10 : 699-1087
 
Bamias A., Tiliakos I., Karali M.D., Dimopoulos M.A. Systemic chemotherapy in inoperable or metastatic bladder cancer Ann Oncol 2006 ;  17 : 553-561Epub 2005 Nov 22.  [cross-ref]
 
Esrig D., Elmajian D., Groshen S., Freeman J.A., Stein J.P., Chen S.C., et al. Accumulation of nuclear p53 and tumor progression in bladder cancer N Engl J Med 1994 ;  331 (19) : 1259-1264 [cross-ref]
 
Cote R.J., Dunn M.D., Chatterjee S.J., Stein J.P., Shi S.R., Tran Q.C., et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53 Cancer Res 1998 ;  58 : 1090-1094
 
Benedict W.F., Lerner S.P., Zhou J., Shen X., Tokunaga H., Czerniak B. Level of retinoblastoma protein-1,5 expression correlates with 16p (MTS-1/INK4A/CDKN2) status in bladder cancer Oncogene 1999 ;  18 : 1197-1203 [cross-ref]
 
Chatterjee S.J., Datar R., Youssefzadeh D., George B., Goebell P.J., Stein J.P., et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma J Clin Oncol 2004 ;  22 : 1007-1013 [cross-ref]
 
Shariat S.F., Tokunaga H., Zhou J., Kim J., Ayala G.E., Benedict W.F., et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer J Clin Oncol 2004 ;  22 : 1014-1024 [cross-ref]
 
Lebret T., Watson R.W., Fitzpatrick J.M. Heat shock proteins: their role in urological tumors J Urol 2003 ;  169 : 338-346 [cross-ref]
 
Finlay C.A., Hinds P.W., Tan T.H., Eliyahu D., Oren M., Levine A.J. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered halflife Mol Cell Biol 1988 ;  8 : 531-539 [cross-ref]
 
Jolly C., Morimoto R.I. Role of the heat shock response and molecular chaperones in oncogenesis and cell death J Natl Cancer Inst 2000 ;  92 : 1564-1572 [cross-ref]
 
Cote R.J., Esrig D., Groshen S., Jones P.A., Skinner D.G. p53 and treatment of bladder cancer Nature 1997 ;  385 : 123-125 [cross-ref]
 
Raghavan D. Molecular targeting and pharmacogenomics in the management of advanced bladder cancer Cancer 2003 ;  97 : 2083-2089 [cross-ref]
 
Cote R.J., Datar R.H. Therapeutic approaches to bladder cancer: identifying targets and mechanisms Crit Rev Oncol Hematol 2003 ;  46 : S67-S83 [cross-ref]
 
Hanahan D., Weinberg R.A. The hallmarks of cancer Cell 2000 ;  100 : 57-70 [cross-ref]
 
Casey P.J., Seabra M.C. Protein prenyltransferases J Biol Chem 1996 ;  271 : 5289-5292 [cross-ref]
 
Sebti S.M. Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy Cancer Cell 2005 ;  7 : 297-300 [cross-ref]
 
Shinohara N., Koyanagi T. Ras signal transduction in carcinogenesis and progression of bladder cancer: molecular target for treatment? Urol Res 2002 ;  30 : 273-281 [cross-ref]
 
Rosenberg J.E., von der Maase H., Seigne J.D., Mardiak J., Vaughn D.J., Moore M., et al. A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma Cancer 2005 ;  103 : 2035-2041 [cross-ref]
 
Winquist E., Moore M.J., Chi K.N., Ernst D.S., Hirte H., North S., et al. A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer Urol Oncol 2005 ;  23 : 143-149 [cross-ref]
 
Theodore C., Geoffrois L., Vermorken J.B., Caponigro F., Fiedler W., Chollet P., et al. Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers Eur J Cancer 2005 ;  41 : 1150-1157 [cross-ref]
 
Chow N.H., Liu H.S., Lee E.I., Chang C.J., Chan S.H., Cheng H.L., et al. Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer Anticancer Res 1997 ;  17 : 1293-1296
 
Neal D.E., Mellon K. Epidermal growth factor receptor and bladder cancer: a review Urol Int 1992 ;  48 : 365-371 [cross-ref]
 
Black P.C., Dinney C.P. Growth factors and receptors as prognostic markers in urothelial carcinoma Curr Urol Rep 2008 ;  9 : 55-61 [cross-ref]
 
Sauter G., Haley J., Chew K., Kerschmann R., Moore D., Carroll P., et al. Epidermal-growth-factor-receptor expression is associated with rapid tumor proliferation in bladder cancer Int J Cancer 1994 ;  57 : 508-514 [cross-ref]
 
Schaub N.P., Maloney N., Schneider H., Feliberti E., Perry R. Changes in male breast cancer over a 30-year period Am Surg 2008 ;  74 : 711-712discussion 707-11.
 
Pollera C.F., Nelli F. Developing innovative strategies for advanced transitional cell carcinoma of the bladder Expert Rev Anticancer Ther 2006 ;  6 : 83-92 [cross-ref]
 
Wallerand H., Robert G., Bernhard J.C., Ravaud A., Ferrière J.M. Les thérapeutiques ciblées du cancer de vessie localement avancé et/ou métastatique Prog Urol 2008 ;  18 : 407-417 [inter-ref]
 
Amsellem-Ouazana D., Bièche I., Tozlu S., Botto H., Debré B., Lidereau R. Gene expression profiling of ERBB receptors and ligands in human transitional cell carcinoma of the bladder J Urol 2006 ;  175 : 1127-1132 [cross-ref]
 
Tetu B., Fradet Y., Allard P., Veilleux C., Roberge N., Bernard P. Prevalence and clinical significance of HER/2neu, p53 and Rb expression in primary superficial bladder cancer J Urol 1996 ;  155 : 1784-1788 [cross-ref]
 
Underwood M., Bartlett J., Reeves J., Gardiner D.S., Scott R., Cooke T. C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? Cancer Res 1995 ;  55 : 2422-2430
 
Lönn U., Lönn S., Friberg S., Nilsson B., Silfverswärd C., Stenkvist B. Prognostic value of amplification of c-erb-B2 in bladder carcinoma Clin Cancer Res 1995 ;  1 : 1189-1194
 
Bakkar A.A., Quach V., Le Borgne A., Toublanc M., Henin D., Wallerand H., Radvanyi F., Bittard H., Ravery V., Gibod L.B., de Medina S.G., Chopin D.K., Grandchamp B. Sensitive allele-specific PCR assay able to detect FGFR3 mutations in tumors and urine from patients with urothelial cell carcinoma of the bladder Clin Chem 2005 ;  51 : 1555-1557 [cross-ref]
 
Radvanyi F. Analysis of bladder tumors by transcryptome analysis: a common adventure with Dominique Chopin Prog Urol 2005 ;  15 : 1221-1224
 
Jimenez R.E., Hussain M., Bianco F.J., Vaishampayan U., Tabazcka P., Sakr W.A., et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors Clin Cancer Res 2001 ;  7 : 2440-2447
 
Hussain M.H., MacVicar G.R., Petrylak D.P., Dunn R.L., Vaishampayan U., Lara P.N., et al. National Cancer Institute. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial J Clin Oncol 2007 ;  25 : 2218-2224Erratum in: J Clin Oncol 2008;26:3295.  [cross-ref]
 
Peyromaure M., Scotté F., Amsellem-Ouazana D., Vieillefond A., Oudard S., Beuzeboc P. Trastuzumab (Herceptin) in metastatic transitional cell carcinoma of the urinary tract: report on six patients Eur Urol 2005 ;  48 : 771-775discussion 775-8.
 
Black P.C., Brown G.A., Inamoto T., Shrader M., Arora A., Siefker-Radtke A.O., et al. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells Clin Cancer Res 2008 ;  14 : 1478-1486 [cross-ref]
 
Garcia J.A., Dreicer R. Systemic chemotherapy for advanced bladder cancer: update and controversies J Clin Oncol 2006 ;  24 : 5545-5551 [cross-ref]
 
Bellmunt J., Hussain M., Dinney C.P. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family Crit Rev Oncol Hematol 2003 ;  46 : S85-104 [cross-ref]
 
Petrylak D., Faulkner J.R., Van Veldhuizen P.J., et al. Evaluation of ZD 1839 for advanced transitional cell carclnoma (TCC) of the urothellum:A Southwest Oncology Group Trial Proc Am Soc Clin Oncol 2003 ;  2203 : (Abstract 1619).
 
Philips G., Halabl S., Sanford B., et al. Phase II trial of cisplatin (C), fixed-dose rate gemcitablne (G) and gefitinib for advanced transitlonal cell carclnoma (TCC) of the urothellal tract: prellmlnary results of CALGB 90102 Proc Am Soc Clin Oncol 2004 ;  23 : 390(abstract 4540).
 
Slaton J.W., Millikan R., Inoue K., Karashima T., Czerniak B., Shen Y., et al. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy J Urol 2004 ;  171 : 570-574 [cross-ref]
 
Yang J.L., Qu X.J., Hayes V.M., Brenner P.C., Russell P.J., Goldstein D. Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferonalpha BJU Int 2007 ;  99 : 1539-1545Epub 2007 Mar 6.  [cross-ref]
 
Morgan M.A., Parsels L.A., Kollar L.E., Normolle D.P., Maybaum J., Lawrence T.S. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer Clin Cancer Res 2008 ;  14 : 5142-5149 [cross-ref]
 
Silay M.S., Miroglu C. Sunitinib malate and sorafenib may be beneficial at the treatment of advanced bladder cancer due to their anti-angiogenic effects Med Hypotheses 2007 ;  69 : 892-895 [cross-ref]
 
Bradley D.A., Dunn R., Nanus D., Stadler W., Dreicer R., Rosenberg J., et al. Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design Clin Genitourin Cancer 2007 ;  5 : 460-463 [cross-ref]
 
Wülfing C., Machiels I., Richel D., et al. A single arm, multicenter open label, ph II study of lapatinib as 2nd treatment of pts with locally advanced metastatic transltional cell carcinoma (TCC) of the urothelial tract Proc Am Soc Clin Oncol 2005 ;  24 : 401(Abstract 4594).
 
Garcia J.A., Dreicer R. Systemic chemotherapy for advanced bladder cancer: update and controversies J Clin Oncol 2006 ;  24 : 5545-5551 [cross-ref]
 
Beekman K.W., Bradley D., Hussain M. New molecular targets and novel agents in the treatment of advanced urothelial cancer Semin Oncol 2007 ;  34 : 154-164 [cross-ref]
 
Cordon-Cardo C. Molecular biology of bladder cancer. AscoGU. San Francisco, 2008, proceedings, 46-48.
 
Cappellen D., De Oliveira C., Ricol D., de Medina S., Bourdin J., Sastre-Garau X., et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas Nat Genet 1999 ;  23 : 18-20
 
Jebar A.H., Hurst C.D., Tomlinson D.C., Johnston C., Taylor C.F., Knowles M.A. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma Oncogene 2005 ;  24 : 5218-5225 [cross-ref]
 
Knowles M.A. Molecular pathogenesis of bladder cancer Int J Clin Oncol 2008 ;  13 : 287-297 [cross-ref]
 
Sibley K., Cuthbert-Heavens D., Knowles M.A. Loss of heterozygosity at 4p16. 3 and mutation of FGFR3 in transitional cell carcinoma Oncogene 2001 ;  20 : 686-691 [cross-ref]
 
Billerey C., Chopin D., Aubriot-Lorton M.H., Ricol D., Gil Diez de Medina S., Van Rhijn B., et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors Am J Pathol 2001 ;  158 : 1955-1959 [cross-ref]
 
van Rhijn B.W., Lurkin I., Radvanyi F., Kirkels W.J., van der Kwast T.H., Zwarthoff E.C. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate Cancer Res 2001 ;  61 : 1265-1268
 
Hernández S., López-Knowles E., Lloreta J., Kogevinas M., Amorós A., Tardón A., et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas J Clin Oncol 2006 ;  24 : 3664-3671
 
van Rhijn B.W., van Tilborg A.A., Lurkin I., Bonaventure J., de Vries A., Thiery J.P., et al. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders Eur J Hum Genet 2002 ;  10 : 819-824 [cross-ref]
 
Slaton J.W., Millikan R., Inoue K., Karashima T., Czerniak B., Shen Y., et al. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy J Urol 2004 ;  171 : 570-574 [cross-ref]
 
Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 2004 ;  350 : 2335-2342 [cross-ref]
 
Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 2003 ;  349 : 427-434 [cross-ref]
 
Bellmunt J., Maroto P., Mellado B., et al. Phase II study of sunitinib as first line treatment in patients with advanced urothelial cancer ineligible for cisplatin based chemotherapy ASO GU San Francisco 2008 ; 14-16 February Astract 291.
 
Sridhar S.S., Winquist E., Eisen S., et al. A phase II study of first line sorafenib in advanced or metastatic urothelial cancer. A trial of the PMH Phase II consortium ASO GU San Francisco 2008 ; 34014-16 February Astract.
 
Inoue K., Chikazawa M., Fukata S., Yoshikawa C., Shuin T. Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470 at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder Clin Cancer Res 2002 ;  8 : 2389-2398
 
Rosell R., Taron M., Ariza A., Barnadas A., Mate J.L., Reguart N., et al. Molecular predictors of response to chemotherapy in lung cancer Semin Oncol 2004 ;  31 : 20-27 [cross-ref]
 
Takata R., Katagiri T., Kanehira M., Tsunoda T., Shuin T., Miki T., et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling Clin Cancer Res 2005 ;  11 : 2625-2636 [cross-ref]
 
   
 
 
   

 

© 2008  Elsevier Masson SAS. Tous droits réservés.